Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 10/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.37 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.34 |
| ▸ | ADK | P55263 | 5/20 | 0.33 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | SIK1 | P57059 | 1/20 | 0.32 |
| ▸ | RIPK4 | P57078 | 1/20 | 0.32 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | DSTYK | Q6XUX3 | 1/20 | 0.32 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17772331 | 0.82 | STING1 (0.52) | STING1 | |
| SCHEMBL12595500 | 0.82 | STING1 (0.52) | STING1 | |
| SCHEMBL12352439 | 0.82 | STING1 (0.52) | STING1 | |
| SCHEMBL12222444 | 0.82 | STING1 (0.52) | STING1 | |
| SCHEMBL8624094 | 0.82 | STING1 (0.52) | STING1 | |
| SCHEMBL12729578 | 0.82 | STING1 (0.52) | STING1 | |
| SCHEMBL22758710 | 0.80 | ATG7 (0.35) | STING1 | |
| SCHEMBL22758780 | 0.80 | ATG7 (0.34) | STING1 | |
| SCHEMBL22758826 | 0.80 | ATG7 (0.34) | STING1 | |
| SCHEMBL22758825 | 0.80 | ATG7 (0.34) | STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2021-07-08 | — | — | US | disclosed |
| EP-3727401-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | PRMT5 4024/4885WDR77 3132/4885STING1 1/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | PRMT5 4092/4885WDR77 3180/4885STING1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.